Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236040 | 0.94 | NPC1 (0.55) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL26407280 | 0.84 | RAB9A (0.69) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL9265040 | 0.82 | RAB9A (0.79) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL6707186 | 0.82 | RAB9A (0.79) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL28422020 | 0.80 | CDK5 (0.48) | L3MBTL1RAB9ANPC1PKMACACB | |
| SCHEMBL19891611 | 0.80 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL19445791 | 0.78 | RAB9A (0.72) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL22031528 | 0.78 | USP30 (0.55) | KDM4EPKM | |
| SCHEMBL23384768 | 0.77 | SMYD3 (0.76) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL31070870 | 0.77 | L3MBTL1 (0.68) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | L3MBTL1 3936/4885RAB9A 1101/4885NPC1 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.